Fig. 1From: Adding colchicine to immunosuppressive treatments; a potential option for biologics-refractory adult-onset Still’s diseaseClinical course of the patient. PSL prednisolone, TAC tacrolimus, MTX methotrexate, TCZ tocilizumab, iv. intravenous, sc. subcutaneous, IFX infliximab, CyA cyclosporine, CRP C-reactive protein, SSA serum amyloid ABack to article page